Marietta, Ga.-based MiMedx Group's EpiFix diabetic foot ulcer treatment will now be covered by Hartford, Conn.-based payer Aetna.
Aetna's approximately 17.5 million commercial members gained coverage for EpiFix effective Dec. 23. EpiFix treats partial and full-thickness neuropathic diabetic foot ulcers, a complication of diabetes and often a precursor to lower-extremity amputation. Aetna deemed EpiFix medically necessary for treatment of foot ulcers lasting more than six weeks with no capsule, tendon or bone exposed, when used with standard diabetic ulcer care.
"The clinical efficacy and cost effectiveness of tissues and products are heavily scrutinized by the commercial health plans," Bill Taylor, president and COO of MiMedx, said in a prepared statement. "It is clear to us that the evidence demonstrating that our allografts benefit their members clinically, as well as provide more cost effective care, has been a significant factor in our success in attaining coverage awards from insurers."
More articles about payer issues:
Study: Medicaid expansion linked to greater employment among people with disabilities
How Big Bang Health Mission Control is tackling healthcare's inefficiencies: 5 key thoughts
S&P predicts ACA marketplace insurers will see results improve in 2016-17